ACELYRIN INC (SLRN)
US00445A1007 - Common Stock
Which stocks are gapping on Thursday?
These stocks are gapping in today's session
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC....
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024.
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acelyrin (NASDAQ:SLRN) just reported results for the second quarter of 2024.Ace...
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks Company to prioritize development of lonigutamab; dose...
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
Commit To Purchase ACELYRIN At $5, Earn 99.5% Annualized Using Options
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
LOS ANGELES, June 05, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
ACELYRIN Becomes Oversold (SLRN)
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024.
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acelyrin (NASDAQ:SLRN) just reported results for the first quarter of 2024.Acel...
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month;...
ACELYRIN, INC. Announces Leadership Transition
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the...
Commit To Buy ACELYRIN At $2.50, Earn 25.2% Annualized Using Options
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023.
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acelyrin (NASDAQ:SLRN) just reported results for the fourth quarter of 2023.Ace...
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease...
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Noteworthy Monday Option Activity: SLRN, OLED, AMBC
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational...